168 related articles for article (PubMed ID: 12170763)
1. Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor.
Gurova KV; Kwek SS; Koman IE; Komarov AP; Kandel E; Nikiforov MA; Gudkov AV
Cancer Biol Ther; 2002; 1(1):39-44. PubMed ID: 12170763
[TBL] [Abstract][Full Text] [Related]
2. A fly with an ointment: Bcl-2 as an anti-mutator in tumors.
Gottlieb E
Cancer Biol Ther; 2002; 1(1):45-6. PubMed ID: 12197483
[No Abstract] [Full Text] [Related]
3. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.
Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC
Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
5. Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence.
Nikiforov MA; Kwek SS; Mehta R; Artwohl JE; Lowe SW; Gupta TD; Deichman GI; Gudkov AV
Oncogene; 1997 Dec; 15(25):3007-12. PubMed ID: 9444949
[TBL] [Abstract][Full Text] [Related]
6. Mutations in apoptosis genes: a pathogenetic factor for human disease.
Müllauer L; Gruber P; Sebinger D; Buch J; Wohlfart S; Chott A
Mutat Res; 2001 Jul; 488(3):211-31. PubMed ID: 11397650
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
8. The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents.
Gillet R; Grimber G; Bennoun M; Caron de Fromentel C; Briand P; Joulin V
Oncogene; 2000 Jul; 19(31):3498-507. PubMed ID: 10918608
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical role of apoptosis in tumor progression.
Gurova KV; Gudkov AV
J Cell Biochem; 2003 Jan; 88(1):128-37. PubMed ID: 12461782
[TBL] [Abstract][Full Text] [Related]
10. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent.
Trudel M; Lanoix J; Barisoni L; Blouin MJ; Desforges M; L'Italien C; D'Agati V
J Exp Med; 1997 Dec; 186(11):1873-84. PubMed ID: 9382886
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Trepel M; Groscurth P; Malipiero U; Gulbins E; Dichgans J; Weller M
J Neurooncol; 1998 Aug; 39(1):19-32. PubMed ID: 9760067
[TBL] [Abstract][Full Text] [Related]
12. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
Eastham JA; Grafton W; Martin CM; Williams BJ
J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
[TBL] [Abstract][Full Text] [Related]
13. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA.
Shou J; Ali-Osman F; Multani AS; Pathak S; Fedi P; Srivenugopal KS
Oncogene; 2002 Jan; 21(6):878-89. PubMed ID: 11840333
[TBL] [Abstract][Full Text] [Related]
14. Alterations in cell cycle control during tumor progression: effects on apoptosis and the response to therapeutic agents.
Muschel RJ; McKenna WG
Curr Top Microbiol Immunol; 1996; 213 ( Pt 2)():197-213. PubMed ID: 9053291
[No Abstract] [Full Text] [Related]
15. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
17. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
Wang H; Mohammad RM; Werdell J; Shekhar PV
Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625
[TBL] [Abstract][Full Text] [Related]
18. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.
Nishizaki M; Fujiwara T; Tanida T; Hizuta A; Nishimori H; Tokino T; Nakamura Y; Bouvet M; Roth JA; Tanaka N
Clin Cancer Res; 1999 May; 5(5):1015-23. PubMed ID: 10353734
[TBL] [Abstract][Full Text] [Related]
19. [Role of the p53 and bcl-2 genes in apoptosis and drug resistance of tumors].
Luk'ianova NIu; Kulik GI; Chehun VF
Vopr Onkol; 2000; 46(2):121-8. PubMed ID: 10853407
[No Abstract] [Full Text] [Related]
20. Loss of p53 in F-MuLV induced-erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence.
Wong KS; Li YJ; Howard J; Ben-David Y
Oncogene; 1999 Sep; 18(40):5525-34. PubMed ID: 10523829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
